{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T08:18:03Z","timestamp":1783325883020,"version":"3.54.6"},"reference-count":60,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Methotrexate (MTX) is a widely used, cost-effective systemic treatment for moderate-to-severe psoriasis, but concerns about hepatotoxicity often limit its long-term use. Hepatic adverse effects range from transient enzyme elevations to fibrosis and cirrhosis. Despite established guidelines, monitoring practices remain inconsistent, and the mechanisms underlying MTX-induced hepatotoxicity in psoriasis patients are not fully elucidated. This systematic literature review evaluates the association between MTX and hepatotoxicity, identifies key risk factors, assesses monitoring strategies and addresses misconceptions about its hepatic safety. A comprehensive search of MEDLINE\/PubMed, EMBASE, Cochrane Library and grey literature (2003\u20132024) included English and French studies on human subjects, encompassing guidelines, reviews and observational\/interventional studies. MTX-related hepatotoxicity is multifactorial, with risk factors including obesity, diabetes, hyperlipidaemia, excessive alcohol consumption and pre-existing liver disease. Psoriasis itself may also contribute to liver dysfunction. There is no consensus on optimal monitoring frequency for liver function tests or the role of noninvasive tools like transient elastography. While folic acid supplementation may mitigate risk, dosing remains inconsistent.Though MTX carries a potential hepatotoxic risk, this is patient-specific rather than inherent to the drug. Standardized monitoring protocols and risk stratification are essential to optimize safety, prevent unnecessary treatment discontinuation and improve long-term psoriasis management.<\/jats:p>","DOI":"10.2340\/actadv.v106.adv-2025-0021","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T07:48:26Z","timestamp":1783324106000},"source":"Crossref","is-referenced-by-count":0,"title":["A Systematic Literature Review on Methotrexate Hepatotoxicity in Psoriasis Management: Preconceived Notion or Real Threat?"],"prefix":"10.2340","volume":"106","author":[{"given":"Wolf-Henning","family":"Boehncke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Magdalena","family":"Constantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Manuel","family":"Carrascosa-Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pariyawan","family":"Rakvit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice-Ana\u00efs","family":"Varlet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solenn","family":"Le Clanche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda A.W.","family":"Verhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuelle","family":"Viguier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"162010","doi-asserted-by":"crossref","unstructured":"Chat VS, Uppal SK, Kearns DG, Han G, Wu JJ. Translating the 2020 AAD-NPF guidelines of care for the management of psoriasis with systemic nonbiologics to clinical practice. Cutis 2021; 107: 99\u2013103.","DOI":"10.12788\/cutis.0177"},{"key":"162011","doi-asserted-by":"crossref","unstructured":"Boehncke WH, Sch\u00f6n MP. Psoriasis. Lancet 2015; 386: 983\u2013994.","DOI":"10.1016\/S0140-6736(14)61909-7"},{"key":"162012","doi-asserted-by":"crossref","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet 2021; 397: 1301\u20131315.","DOI":"10.1016\/S0140-6736(20)32549-6"},{"key":"162013","doi-asserted-by":"crossref","unstructured":"Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol 2020; 16: 145\u2013154.","DOI":"10.1038\/s41584-020-0373-9"},{"key":"162014","doi-asserted-by":"crossref","unstructured":"Ezhilarasan D. Hepatotoxic potentials of methotrexate: understanding the possible toxicological molecular mechanisms. Toxicology 2021; 458: 152840.","DOI":"10.1016\/j.tox.2021.152840"},{"key":"162015","doi-asserted-by":"crossref","unstructured":"Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology\u2013National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol 2020; 82: 1445\u20131486.","DOI":"10.1016\/j.jaad.2020.02.044"},{"key":"162016","doi-asserted-by":"crossref","unstructured":"Y\u00e9lamos O, Puig L. Systemic methotrexate for the treatment of psoriasis. Expert Rev Clin Immunol 2015; 11: 553\u2013563.","DOI":"10.1586\/1744666X.2015.1026894"},{"key":"162017","doi-asserted-by":"crossref","unstructured":"Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol 2012; 148: 95\u2013102.","DOI":"10.1001\/archdermatol.2011.1410"},{"key":"162018","doi-asserted-by":"crossref","unstructured":"Munera-Campos M, Vilar-Alejo J, Rivera R, Carrascosa JM, Daud\u00e9n E, Herrera-Acosta E, et al. The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry. J Dermatolog Treat 2022; 33: 2110\u20132117.","DOI":"10.1080\/09546634.2021.1922572"},{"key":"162019","doi-asserted-by":"crossref","unstructured":"Mahajan R, Dogra S, Handa S, Razmi Tm, Narang T, Rathi S, et al. Metabolic syndrome and female gender, but not methotrexate, are the important associations of significant liver fibrosis in patients with moderate-to-severe psoriasis as detected by transient elastography. Indian J Dermatol Venereol Leprol 2020; 86: 649.","DOI":"10.4103\/ijdvl.IJDVL_152_19"},{"key":"162020","doi-asserted-by":"crossref","unstructured":"Tang KT, Chen YM, Chang SN, Lin CH, Chen DY. Psoriatic patients with chronic viral hepatitis do not have an increased risk of liver cirrhosis despite long-term methotrexate use: real-world data from a nationwide cohort study in Taiwan. J Am Acad Dermatol 2018; 79: 652\u2013658.","DOI":"10.1016\/j.jaad.2018.05.004"},{"key":"162021","doi-asserted-by":"crossref","unstructured":"Conway R, Low C, Coughlan RJ, O\u2019Donnell MJ, Carey JJ. Risk of liver injury among methotrexate users: a meta-analysis of randomised controlled trials. Semin Arthritis Rheum 2015; 45: 156\u2013162.","DOI":"10.1016\/j.semarthrit.2015.05.003"},{"key":"162022","doi-asserted-by":"crossref","unstructured":"Fiore M, Leone S, Maraolo AE, Berti E, Damiani G. Liver illness and psoriatic patients. Biomed Res Int 2018; 2018: 3140983.","DOI":"10.1155\/2018\/3140983"},{"key":"162023","doi-asserted-by":"crossref","unstructured":"Gisondi P, Bellinato F, Bruni M, De Angelis G, Girolomoni G. Methotrexate vs secukinumab safety in psoriasis patients with metabolic syndrome. Dermatol Ther 2020; 33: 33.","DOI":"10.1111\/dth.14281"},{"key":"162024","doi-asserted-by":"crossref","unstructured":"Reich K, Augustin M, Tha\u00e7i D, Pinter A, Leutz A, Henneges C, et al. A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment. Br J Dermatol 2020; 182: 869\u2013879.","DOI":"10.1111\/bjd.18384"},{"key":"162025","doi-asserted-by":"crossref","unstructured":"Kt S, Thakur V, Narang T, Dogra S, Handa S. Comparison of the efficacy and safety of apremilast and methotrexate in patients with palmoplantar psoriasis: a randomized controlled trial. Am J Clin Dermatol 2021; 22: 415\u2013423.","DOI":"10.1007\/s40257-021-00596-6"},{"key":"162026","doi-asserted-by":"crossref","unstructured":"West J, Ogston S, Foerster J. Safety and efficacy of methotrexate in psoriasis: a meta-analysis of published trials. PLoS One 2016; 11: e0153740.","DOI":"10.1371\/journal.pone.0153740"},{"key":"162027","doi-asserted-by":"crossref","unstructured":"Mazhar F, Krantz \u00c5, Schalin L, Lysell J, Carrero JJ. Occurrence of adverse events associated with the initiation of methotrexate and biologics for the treatment of psoriasis in routine clinical practice. J Dermatolog Treat 2023; 34: 2215354.","DOI":"10.1080\/09546634.2023.2215354"},{"key":"162028","doi-asserted-by":"crossref","unstructured":"Ozkok Akbulut T, Topaloglu Demir F, Oguz Topal I, Kara Polat A, Karadag AS, Aslan Kayiran M, et al. Drug survival and predictor factors for discontinuation of methotrexate in psoriasis: a real-life multicenter study. Int J Dermatol 2021; 60: 1140\u20131147.","DOI":"10.1111\/ijd.15628"},{"key":"162029","doi-asserted-by":"crossref","unstructured":"Cabello Zurita C, Grau P\u00e9rez M, Hern\u00e1ndez Fern\u00e1ndez CP, Gonz\u00e1lez Quesada A, Valer\u00f3n Almaz\u00e1n P, Vilar Alejo J, et al. Effectiveness and safety of Methotrexate in psoriasis: an eight-year experience with 218 patients. J Dermatolog Treat 2017; 28: 401\u2013405.","DOI":"10.1080\/09546634.2016.1273469"},{"key":"162030","doi-asserted-by":"crossref","unstructured":"Drach M, Papageorgiou K, Maul JT, Djamei V, Yawalkar N, H\u00e4usermann P, et al. Effectiveness of methotrexate in moderate to severe psoriasis patients: real-world registry data from the Swiss Dermatology Network for Targeted Therapies (SDNTT). Arch Dermatol Res 2019; 311: 753\u2013760.","DOI":"10.1007\/s00403-019-01945-6"},{"key":"162031","doi-asserted-by":"crossref","unstructured":"Tula E, Ergun T, Seckin D, Ozgen Z, Avsar E. Psoriasis and the liver: problems, causes and course. Australas J Dermatol 2017; 58: 194\u2013199.","DOI":"10.1111\/ajd.12460"},{"key":"162032","doi-asserted-by":"crossref","unstructured":"Gelfand JM, Wan J, Zhang H, Shin DB, Ogdie A, Syed MN, et al. Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis receiving methotrexate: a population-based study. J Am Acad Dermatol 2021; 84: 1636\u20131643.","DOI":"10.1016\/j.jaad.2021.02.019"},{"key":"162033","doi-asserted-by":"crossref","unstructured":"Yan K, Zhang Y, Han L, Huang Q, Zhang Z, Fang X, et al. Safety and efficacy of methotrexate for Chinese adults with psoriasis with and without psoriatic arthritis. JAMA Dermatol 2019; 155: 327\u2013334.","DOI":"10.1001\/jamadermatol.2018.5194"},{"key":"162034","doi-asserted-by":"crossref","unstructured":"Dogra S, Singh N, Kumar S, Narang T, Handa S. Comparison of overall efficacy and safety of oral versus subcutaneous methotrexate in severe psoriasis. Dermatol Ther 2022; 35: e15656.","DOI":"10.1111\/dth.15656"},{"key":"162035","doi-asserted-by":"crossref","unstructured":"Choonhakarn C, Chaowattanapanit S, Julanon N, Limpawattana P. Comparison of the clinical efficacy of subcutaneous vs. oral administration of methotrexate in patients with psoriasis vulgaris: a randomized controlled trial. Clin Exp Dermatol 2022; 47: 942\u2013948.","DOI":"10.1111\/ced.15102"},{"key":"162036","doi-asserted-by":"crossref","unstructured":"Viguier M, Carrascosa-Carrillo JM, Rakvit P, Constantin MM, Varlet AA, Le Clanche S, et al. Comprehensive literature review evaluating the use, safety, and efficacy of subcutaneous methotrexate in the treatment of adult patients with moderate-to-severe plaque-type psoriasis. Int J Dermatol 2025; 64: 1558\u20131567.","DOI":"10.1111\/ijd.17758"},{"key":"162037","doi-asserted-by":"crossref","unstructured":"Geel MJ van, Oostveen AM, Hoppenreijs EPAH, Hendriks JCM, Kerkhof PCM van de, de Jong EMGJ, et al. Methotrexate in pediatric plaque-type psoriasis: long-term daily clinical practice results from the Child-CAPTURE registry. J Dermatolog Treat 2015; 26: 406\u2013412.","DOI":"10.3109\/09546634.2014.996515"},{"key":"162038","doi-asserted-by":"crossref","unstructured":"Sahin G, Aydin F, Pancar Yuksel E. Systemic treatments in pediatric psoriasis: a retrospective single-center study. Arch Iran Med 2021; 24: 903\u2013909.","DOI":"10.34172\/aim.2021.135"},{"key":"162039","doi-asserted-by":"crossref","unstructured":"Ergun T, Seckin Gencosmanoglu D, Alpsoy E, Bulbul-Baskan E, Saricam MH, Salman A, et al. Efficacy, safety and drug survival of conventional agents in pediatric psoriasis: a multicenter, cohort study. J Dermatol 2017; 44: 630\u2013634.","DOI":"10.1111\/1346-8138.13713"},{"key":"162040","doi-asserted-by":"crossref","unstructured":"Wang Z, Chen Y, Xiang X, Gu Y, Zhao M, Liu Y, et al. Systemic methotrexate treatment in 42 children with severe plaque psoriasis: a retrospective study in China. Dermatology 2022; 238: 919\u2013927.","DOI":"10.1159\/000521262"},{"key":"162041","doi-asserted-by":"crossref","unstructured":"Klufas DM, Wald JM, Strober BE. Treatment of moderate to severe pediatric psoriasis: a retrospective case series. Pediatr Dermatol 2016; 33: 142\u2013149.","DOI":"10.1111\/pde.12782"},{"key":"162042","doi-asserted-by":"crossref","unstructured":"van Winden MEC, van der Schoot LS, van de L\u2019Isle Arias M, van Vugt LJ, van den Reek JMPA, van de Kerkhof PCM, et al. Effectiveness and safety of systemic therapy for psoriasis in older adults: a systematic review. JAMA Dermatol 2020; 156: 1229\u20131239.","DOI":"10.1001\/jamadermatol.2020.2311"},{"key":"162043","doi-asserted-by":"crossref","unstructured":"Lajevardi V, Hallaji Z, Daklan S, Abedini R, Goodarzi A, Abdolreza M. The efficacy of methotrexate plus pioglitazone vs. methotrexate alone in the management of patients with plaque\u2010type psoriasis: a single\u2010blinded randomized controlled trial. Int J Dermatology 2015; 54: 95\u2013101.","DOI":"10.1111\/ijd.12585"},{"key":"162044","doi-asserted-by":"crossref","unstructured":"Singh SK, Singnarpi SR. Safety and efficacy of methotrexate (0.3 mg\/kg\/week) versus a combination of methotrexate (0.15 mg\/kg\/week) with cyclosporine (2.5 mg\/kg\/day) in chronic plaque psoriasis: a randomised non-blinded controlled trial. Indian J Dermatol Venereol Leprol 2021; 87: 214\u2013222.","DOI":"10.25259\/IJDVL_613_19"},{"key":"162045","doi-asserted-by":"crossref","unstructured":"Wilsmann-Theis D, Frambach Y, Philipp S, Weyergraf AJ, Jacobi A, M\u00f6ssner R, et al. Systemic antipsoriatic combination therapy with fumaric acid esters for plaque-type psoriasis: report on 17 cases. Dermatology 2015; 230: 119\u2013127.","DOI":"10.1159\/000367890"},{"key":"162046","doi-asserted-by":"crossref","unstructured":"Abidi A, Rizvi DA, Saxena K, Chaudhary S, Ahmad A. The evaluation of efficacy and safety of methotrexate and pioglitazone in psoriasis patients: a randomized, open-labeled, active-controlled clinical trial. Indian J Pharmacol 2020; 52: 16\u201322.","DOI":"10.4103\/ijp.IJP_88_19"},{"key":"162047","doi-asserted-by":"crossref","unstructured":"Koch K. Psoriasis, transient elastography and methotrexate: monitoring at a tertiary hospital. Aust J Dermatology 2021; 62: 69\u201370.","DOI":"10.1111\/ajd.13395"},{"key":"162048","doi-asserted-by":"crossref","unstructured":"Rongngern P, Chularojanamontri L, Wongpraparut C, Silpa-Archa N, Chotiyaputta W, Pongpaibul A, et al. Diagnostic performance of transient elastography for detection of methotrexate-induced liver injury using Roenigk classification in Asian patients with psoriasis: a retrospective study. Arch Dermatol Res 2017; 309: 403\u2013408.","DOI":"10.1007\/s00403-017-1733-4"},{"key":"162049","doi-asserted-by":"crossref","unstructured":"Talme T, Nikamo P, Rosenberg P, St\u00e5hle M. Transient elastography may improve detection of liver fibrosis in psoriasis patients treated with methotrexate. Acta Derm Venereol 2017; 97: 952\u2013954.","DOI":"10.2340\/00015555-2677"},{"key":"162050","doi-asserted-by":"crossref","unstructured":"Nast A, Amelunxen L, Augustin M, Boehncke W, Dressler C, Gaskins M, et al. S3 guideline for the treatment of psoriasis vulgaris, update \u2013 short version part 1 \u2013 systemic treatment. J Deutsche Derma Gesell 2018; 16: 645\u2013669.","DOI":"10.1111\/ddg.13516"},{"key":"162051","doi-asserted-by":"crossref","unstructured":"Kostovi\u0107 K, \u017du\u017eul K, \u010ceovi\u0107 R, Bukvi\u0107 Mokos Z. Psoriasis in the mature patient: therapeutic approach in the era of biologics. Clin Dermatol 2018; 36: 222\u2013230.","DOI":"10.1016\/j.clindermatol.2017.10.013"},{"key":"162052","doi-asserted-by":"crossref","unstructured":"Nast A, Smith C, Spuls PI, Avila Valle G, Bata\u2010Cs\u00f6rg\u00f6 Z, Boonen H, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris \u2013 part 1: treatment and monitoring recommendations. Acad Dermatol Venereol 2020; 34: 2461\u20132498.","DOI":"10.1111\/jdv.16915"},{"key":"162053","unstructured":"Abramovits W, Schlessinger J. Efficacy and safety of systemic treatments for skin and joint manifestations in patients with psoriasis. J Drugs Dermatol 2020; 19: 306\u2013313."},{"key":"162054","doi-asserted-by":"crossref","unstructured":"Rademaker M, Gupta M, Andrews M, Armour K, Baker C, Foley P, et al. The Australasian Psoriasis Collaboration view on methotrexate for psoriasis in the Australasian setting. Aust J Dermatology 2017; 58: 166\u2013170.","DOI":"10.1111\/ajd.12521"},{"key":"162055","doi-asserted-by":"crossref","unstructured":"Viswanath V, Vasani R. Viva questions from the IJDVL. Indian J Dermatol Venereol Leprol 2017; 83: 137.","DOI":"10.4103\/0378-6323.195077"},{"key":"162056","doi-asserted-by":"crossref","unstructured":"Raaby L, Zachariae C, \u00d8stensen M, Heickendorff L, Thielsen P, Gr\u00f8nb\u00e6k H, et al. Methotrexate use and monitoring in patients with psoriasis: a consensus report based on a Danish expert meeting. Acta Derm Venereol 2017; 97: 426\u2013432.","DOI":"10.2340\/00015555-2599"},{"key":"162057","doi-asserted-by":"crossref","unstructured":"Amatore F, Villani A \u2010P., Tauber M, Viguier M, Guillot B, the Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Soci\u00e9t\u00e9 Fran\u00e7aise de Dermatologie). French guidelines on the use of systemic treatments for moderate\u2010to\u2010severe psoriasis in adults. Acad Dermatol Venereol 2019; 33: 464\u2013483.","DOI":"10.1111\/jdv.15340"},{"key":"162058","unstructured":"National Institute for Health and Care Excellence (NICE). Psoriasis: assessment and management. 2017. [cited 2023 July 5]."},{"key":"162059","doi-asserted-by":"crossref","unstructured":"Krantz \u00c5, Carrero JJ, Yang Y, Schalin L, Lysell J, Mazhar F. Psoriasis\/psoriatic arthritis patients\u2019 long-term treatment patterns and adherence to systemic treatments monitoring recommendations. Acta Derm Venereol 2023; 103: adv6505.","DOI":"10.2340\/actadv.v103.6505"},{"key":"162060","doi-asserted-by":"crossref","unstructured":"Ighani A, Partridge ACR, Shear NH, Lynde C, Gulliver WP, Sibbald C, et al. Comparison of management guidelines for moderate-to-severe plaque psoriasis: a review of phototherapy, systemic therapies, and biologic agents. J Cutan Med Surg 2019; 23: 204\u2013221.","DOI":"10.1177\/1203475418814234"},{"key":"162061","doi-asserted-by":"crossref","unstructured":"Carpentieri A, Pacello L, De Marco IM, Loiacono A, Picconi O, Loconsole F. Retrospective analysis of the effectiveness and costs of traditional treatments for moderate-to-severe psoriasis: a single-center, Italian study. J Dermatolog Treat 2016; 27: 399\u2013405.","DOI":"10.3109\/09546634.2015.1133885"},{"key":"162062","doi-asserted-by":"crossref","unstructured":"Warren RB, Weatherhead SC, Smith CH, Exton LS, Mohd Mustapa MF, Kirby B, et al. British Association of Dermatologists\u2019 guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. Br J Dermatol 2016; 175: 23\u201344.","DOI":"10.1111\/bjd.14816"},{"key":"162063","doi-asserted-by":"crossref","unstructured":"Carrascosa JM, de la Cueva P, Ara M, Puig L, Bordas X, Carretero G, et al. Methotrexate in moderate to severe psoriasis: review of the literature and expert recommendations. Actas Dermosifiliogr 2016; 107: 194\u2013206.","DOI":"10.1016\/j.adengl.2016.01.025"},{"key":"162064","doi-asserted-by":"crossref","unstructured":"Arnone M, Takahashi MDF, Carvalho AVE de, Bernardo WM, Bressan AL, Ramos AMC, et al. Diagnostic and therapeutic guidelines for plaque psoriasis - Brazilian Society of Dermatology. An Bras Dermatol 2019; 94: 76\u2013107.","DOI":"10.1590\/abd1806-4841.2019940211"},{"key":"162065","doi-asserted-by":"crossref","unstructured":"van Huizen AM, Sikkel R, Caron AGM, Menting SP, Spuls PI. Methotrexate dosing regimen for plaque-type psoriasis: an update of a systematic review. J Dermatolog Treat 2022; 33: 3104\u20133118.","DOI":"10.1080\/09546634.2022.2117539"},{"key":"162066","doi-asserted-by":"crossref","unstructured":"Menting SP, Dekker PM, Limpens J, Hooft L, Spuls PI. Methotrexate dosing regimen for plaque-type psoriasis: a systematic review of the use of test-dose, start-dose, dosing scheme, dose adjustments, maximum dose and folic acid supplementation. Acta Derm Venereol 2016; 96: 23\u201328.","DOI":"10.2340\/00015555-2081"},{"key":"162067","doi-asserted-by":"crossref","unstructured":"Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology 2006; 43: 1317\u20131325.","DOI":"10.1002\/hep.21178"},{"key":"162068","doi-asserted-by":"crossref","unstructured":"Ouellette S, Shah R, Razi S, Ashforth G, Wassef C. Fatal low-dose methotrexate toxicity: a case report and literature review. Dermatol Ther 2022; 35: e15945.","DOI":"10.1111\/dth.15945"},{"key":"162069","doi-asserted-by":"crossref","unstructured":"Busger Op Vollenbroek FTM, Doggen CJM, Janssens RWA, Bernelot Moens HJ. Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guidelines. PLoS One 2018; 13: e0194401.","DOI":"10.1371\/journal.pone.0194401"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46482\/54697","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46482\/54699","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46482\/54700","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46482\/54697","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T07:50:00Z","timestamp":1783324200000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/46482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":60,"URL":"https:\/\/doi.org\/10.2340\/actadv.v106.adv-2025-0021","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,6]]}}}